MedicaNatumin develops, manufactures and markets healthcare products based on innovative ingredients and solid scientific research. The Groups’ patented platforms are developed by our research group in collaboration with the Karolinska and Sahlgrenska institutes. MedicaNatinum’s leading brands within dietary supplements, medical devices, and derma cosmetics are largely sold on the Nordic market, but also to consumers around the world. Additionally, we have distribution rights for a number of popular organic foods and skincare products in the Norwegian market.

The foundation of MedicaNatumin’s business is to offer innovative products and strong brands from a sustainable and scientific base.
Our starting point is to have a strong position on the Nordic market while developing international partnerships and export operations.

We have all essential parts of the organisation; innovation and product development based on a strong patent platform, a local production that meets strict hygiene and quality requirements, a well-functioning sales and marketing department, and the entire organization is penetrated by clear roles and responsibilities.

Shares

Aktiestruktur

Antal aktier	375 989 277
Summa emitterat	375 989 277
Antal aktieägare	1 805 st
Antal teckningsoptioner	5 800 000 (1 option = 1 aktie)
ISIN	Aktie SE0001789793

Statistik

Först	0.285
Högst	0.292
Medel	0.285
Lägst	0.276
Senast	0.290
+/- Sek	0.00
+/- %	0.00
Omsättning	71034.128
Volym	248900
ISIN	SE0001789793

Aktieägare

Aktieägare	Antal aktier	Andel (ca)
N.P.H i Habo AB	75 000 000	19,95%
Avanza Pension	42 289 096	11,25%
Swedbank Försäkring AB	36 302 287	9,66%
TJ Gruppen AB	18 825 590	5,01%
Jool Invest AB	17 448 434	4,64%
Jesper Pettersson	9 900 000	2,63%
Karl-Olov Eriksson	6 119 725	1,63%
Nordnet Pensionsförsäkring AB	5 907 713	1,57%
Jörgen Wehmonen	5 879 447	1,56%
Lars-Olof Johansson	4 288 953	1,14%
Summa	221 961 245	59,03%
Övriga 1 795 aktieägare	154 028 032	40,97%
Totalt antal aktier	375 989 277	100,00 %